Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Reviva Pharmaceuticals Holdings Inc. | Brilaroxazine (RP5063) | Attention deficit hyperactivity disorder (ADHD) | Phase 2 | Trial Planned | Oral | Psychiatric |
| Reviva Pharmaceuticals Holdings Inc. | Brilaroxazine (RP5063) | Bipolar Disorder (BD) and Major Depressive Disorder (MDD) | Phase 2 | IND Clearance | Oral | Psychiatric |
| Reviva Pharmaceuticals Holdings Inc. | Brilaroxazine | Psoriasis | Phase 2 | IND Clearance | Oral | Immunology |
| Reviva Pharmaceuticals Holdings Inc. | Brilaroxazine (RP5063) | Pulmonary arterial hypertension (PAH) | Phase 2a | Trial Planned | Oral | Cardiology |
| Revolution Medicines Inc - Ordinary Shares | Daraxonrasib (RMC-6236) - (RASolute 302) | Metastatic pancreatic ductal adenocarcinoma (PDAC) | Phase 3 | Ongoing | oral | Oncology |
| Revolution Medicines Inc - Ordinary Shares | Sugemalimab - (GEMSTONE-302) | 1L metastatic non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
| Revolution Medicines Inc - Ordinary Shares | Aumolertinib - (AENEAS) | CNS metastases and EGFR-mutated non-small cell lung cancer (NSCLC) | Phase 3 | Trial Completed | Oral | Oncology |
| Revolution Medicines Inc - Ordinary Shares | Sugemalimab - (GEMSTONE-301) | Stage III Non-small cell lung cancer (NSCLC) | Phase 3 | Trial Completed | Intravenous | Oncology |
